<DOC>
<DOCNO>EP-0646574</DOCNO> 
<TEXT>
<INVENTION-TITLE>
Ketonic indane derivatives, their preparation and therapeutic application thereof
</INVENTION-TITLE>
<CLASSIFICATIONS>C07C28104	C07D21300	C07C28100	C07C28112	C07D21375	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>C07C	C07D	C07C	C07C	C07D	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>C07C281	C07D213	C07C281	C07C281	C07D213	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
The subject of the invention is new ketonic indane derivatives of formula 
<
IMAGE
>
 in which R1 represents a hydrogen or halogen atom or a radical of formula NxR3R3', where x is an integer from 1 to 2 and R3 and R3' are hydrogenated or oxygenated monovalent C1 to C5 organic radicals, X and Y are chosen independently from oxygen or a radical NyR4 where y is an integer from 1 to 2 and R4 is a C1 to C4 alkyl radical or a hydroxyl or alkoxy radical, A is an oxygen atom or a radical NR5 where R5 is a hydrogen atom or a linear or branched C1 to C5 organic radical and R2 is a linear or branched monovalent C1 to C6 organic radical or an aromatic or heteroaromatic ring having one or a number of substituted or unsubstituted heteroatoms, R2 having the above definition with the exception of the phenyl radical or phenyl radical substituted by an alkoxy or hydroxy group when R1 is hydrogen.
</ABSTRACT>
<APPLICANTS>
<APPLICANT-NAME>
INNOTHERA LAB SA
</APPLICANT-NAME>
<APPLICANT-NAME>
LABORATOIRE INNOTHERA SOCIETE ANONYME
</APPLICANT-NAME>
</APPLICANTS>
<INVENTORS>
<INVENTOR-NAME>
DESQUAND STEPHANIE
</INVENTOR-NAME>
<INVENTOR-NAME>
FINET MICHEL
</INVENTOR-NAME>
<INVENTOR-NAME>
LE MARQUER FLORENCE
</INVENTOR-NAME>
<INVENTOR-NAME>
TEMBO NORNERT OLIVIER
</INVENTOR-NAME>
<INVENTOR-NAME>
TORREGROSA JEAN-LUC
</INVENTOR-NAME>
<INVENTOR-NAME>
YANNIC-ARNOULT SYLVIE
</INVENTOR-NAME>
<INVENTOR-NAME>
DESQUAND, STEPHANIE
</INVENTOR-NAME>
<INVENTOR-NAME>
FINET, MICHEL
</INVENTOR-NAME>
<INVENTOR-NAME>
LE MARQUER, FLORENCE
</INVENTOR-NAME>
<INVENTOR-NAME>
TEMBO, NORNERT OLIVIER
</INVENTOR-NAME>
<INVENTOR-NAME>
TORREGROSA, JEAN-LUC
</INVENTOR-NAME>
<INVENTOR-NAME>
YANNIC-ARNOULT, SYLVIE
</INVENTOR-NAME>
</INVENTORS>
<CLAIMS>
Ketone derivatives of indane, characterized in
that they have the following formula:



   where R
1
 represents a hydrogen or halogen
atom, or a radical with formula NR
3
R
3
', where R
3

and R
3
' are monovalent hydrogen-containing or
oxygen-containing C
1
 to C
5
 organic radicals;

X and Y are independently selected from
oxygen, an NR
4
 or N
2
R
4
H radical, where R
4
 is a C
1

to C
4
 alkyl radical, or an alkoxylated radical;
A is an oxygen atom, an NR
5
 radical where R
5

is a hydrogen atom, or a linear or branched C
1
 to
C
5
 organic radical;
R
2
 is a monovalent linear or branched C
1
 to C
6

organic radical or an aromatic or heteroaromatic
cycle containing one or more heteroatoms;
R
2
 having the above definition excluding a
phenyl or substituted phenyl radical when X and Y

are both oxygen and R
1
 is hydrogen, and excluding
the case where R
2
 is a 4-pyridinyl group.
Ketone derivatives of indane according to claim 1,
characterized in that R
1
 is NO
2
, X and Y represent
an oxygen atom, A is an NR
5
 radical where R
5
 
represents a hydrogen atom, and R
2
 is a phenyl
radical.
Ketone derivatives of indane according to claim 1,
characterized in that R
1
 is a hydrogen atom, X and
Y are equivalent and each represent an oxygen

atom, A is an NR
5
 radical where R
5
 represents a
hydrogen atom, and R
2
 is an aromatic cycle
substituted by a nitro derivative.
Ketone derivatives of indane according to claim 1,
characterized in that R
1
 represents a hydrogen
atom, X and Y are equivalent and represent an

oxygen atom, A is an NR
5
 radical where R
5

represents a hydrogen atom, and R
2
 is a
heteroaromatic cycle containing a nitrogen

heteroatom.
Ketone derivatives of indane according to claim 1,
characterized in that R
1
 is a halogen atom, X and
Y are equivalent and each represent an oxygen

atom, A is an NR
5
 radical where R
5
 represents a
hydrogen atom, and R
2
 is a phenyl radical.
Ketone derivatives of indane according to claim 1,
characterized in that R
1
 is a halogen atom, X and
Y are equivalent and each represent an oxygen

atom, A is an NR
5
 radical where R
5
 represents a
hydrogen atom, and R
2
 is a an aromatic cycle
substituted by a halogen atom.
Ketone derivatives of indane according to claim 1,
characterized in that R
1
 is a halogen atom, X and
Y are equivalent and each represent an oxygen 

atom, A is an NR
5
 radical where R
5
 is a hydrogen
atom, and R
2
 is a heteroaromatic cycle containing
a nitrogen heteroatom.
Ketone derivatives of indane according to claim 1,
characterized in that R
1
 is NO
2
, X and Y are
equivalent and represent an oxygen atom, A is an

NR
5
 radical where R
5
 represents a hydrogen atom,
and R
2
 is an aromatic cycle substituted by a
halogen atom.
Ketone derivatives of indane according to claim 1,
characterized in that R
1
 is an NO
2
 radical, X is
analogous to Y and each represents an oxygen atom,

A is an NR
5
 radical where R
5
 represents a hydrogen
atom, and R
2
 is a heteroaromatic cycle containing
a nitrogen heteroatom.
Ketone derivatives of indane according to claim 1,
characterized in that R
1
 represents a hydrogen
atom, X and Y are analogous and each represent an

oxygen atom, A represents an oxygen atom and R
2
 is
a tertiobutyl radical.
Ketone derivatives of indane according to claim 1,
characterized in that R
1
 represents a hydrogen
atom, X and Y are analogous and each represent an

NR
4
 radical where R
4
 is a methyl radical, A
represents an oxygen atom and R
2
 is a tertiobutyl
radical.
Ketone derivatives of indane according to claim 1,
characterized in that R
1
 represents a hydrogen
atom, X and Y are analogous and each represent an 

NR
4
 radical where R
4
 is a methyl radical, A is an
NR
5
 radical where R
5
 represents a hydrogen atom,
and R
2
 is a methyl radical.
Ketone derivatives of indane according to claim 1,
characterized in that R
1
 represents a hydrogen

atom, X and Y are analogous and each represent an
NR
4
 radical where R
4
 is a methyl radical, A is an
NR
5
 radical where R
5
 represents a hydrogen atom,
and R
2
 is a phenyl radical.
Addition salts of mineral acids selected from
hydrochloric acid, hydrobromic acid, sulphuric

acid, phosphoric acid and nitric acid, and of
organic acids selected from acetic acid, propionic

acid, oxalic acid, citric acid, maleic acid,
fumaric acid, succinic acid and tartaric acid with

compounds according to any one of claims 1 to 13.
A process for producing ketone derivatives of
indane, characterized in that it consists of

reacting a compound with formula (I)


   where R
1
 has the meaning defined in claim 1,
with a compound with formula NH
2
-NH-COR
6
 where R
6

is selected from substituted or non substituted 
amines, linear or branched alkoxy radicals,

alkylamino radicals, and substituted or non
substituted arylamino radicals, to obtain a

compound with formula (III):


   then transforming said compound with formula
(III) into a compound with formula:



   where R
7
 is a substituted or non substituted
dioxolane or dioxane group, a substituted or non

substituted imine, or a substituted or non
substituted hydrazine radical, then cleaving the

COR
6
 radical from the compound with formula (IV)
to obtain a compound with formula: 



   then reacting it with a compound with
formula:



   where R
2
 and A have the meanings defined in
claim 1 and R
8
 is an alkoxy radical, to obtain a
compound with formula:



   where R
1
, R
2
, R
7
 and A have the meanings
defined above, to obtain a compound with formula: 



   where R
1
, A and R
2
 have the meanings given
above.
A process for producing ketone derivatives of
indane according to claim 15, characterized in

that radical R
6
 is an o-tertiobutyl radical while
radical R
7
 is a =NCH
3
 radical.
A process for producing ketone derivatives of
indane according to claim 16, characterized in

that a compound with the following formula is
obtained as an intermediate compound:



   where R
7
 is =NCH
3
. 
Use of compounds according to any one of claims 1
to 14 to obtain a drug intended for treatment of

functional organic venous insufficiency.
Use of compounds according to any one of claims 1
to 14 to obtain a drug intended for the treatment

of hemorrhoidal pathologies.
Use of compounds according to any one of claims 1
to 14 to obtain a drug intended for treatment of

osteoarticulatory, dermatological and
cardiovascular inflammatory infections.
Use of compounds according to any one of claims 1
to 14 to obtain a drug intended for treatment of

shock constituted by a substantial drop in blood
pressure, more particularly for septic shock.
2-pyridyl-aminocarbonylhydrazine as an
intermediate product.
3-pyridyl-aminocarbonylhydrazine as an
intermediate product.
</CLAIMS>
</TEXT>
</DOC>
